Thermosome grants Avenor global licence to heat-activated oncology platform and Phase II-ready THE001

Thermosome has granted Avenor Therapeutics exclusive worldwide rights to its heat-activated oncology drug-delivery platform and Phase II-ready THE001 candidate, supporting a combined drug and hyperthermia development strategy.
Thermosome announced on 17 November 2026 that it had entered into an exclusive global licensing agreement with Avenor Therapeutics covering its thermosensitive liposome platform, seven patent families and investigational Phase II-ready THE001 programme, which combines heat-triggered doxorubicin delivery with regional hyperthermia for initial development in soft tissue sarcoma.
Avenor has also secured separate North American rights to a CE-marked hyperthermia system from Medlogix, supporting an integrated drug-device approach; financial terms of the Thermosome agreement were not disclosed, and THE001 remains investigational despite existing orphan-drug designations.
Field | Content |
Licensor | Thermosome |
Licensee | Avenor Therapeutics |
Announcement Date | 17 November 2026 |
Agreement Type | Exclusive global licensing agreement |
Territorial Scope | Worldwide |
Licensed Platform | Thermosensitive liposome drug-delivery technology |
Licensed Intellectual Property | Seven patent families |
Lead Candidate | THE001 |
Development Stage | Phase II-ready |
Therapeutic Area | Oncology |
Initial Indication | Soft tissue sarcoma |
Drug-Delivery Mechanism | Heat-triggered doxorubicin release using regional hyperthermia |
Additional Technology Partner | Medlogix |
Separate Device Rights | North American rights to a CE-marked hyperthermia system |
Financial Terms | Not disclosed |
Regulatory Status | THE001 remains investigational; existing orphan-drug designations do not constitute marketing approval |
Primary Source | https://www.globenewswire.com/news-release/2026/11/17/3404509/0/en/thermosome-closes-exclusive-global-licensing-agreement-with-avenor-therapeutics.html |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments